Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/149941| Title: | Sepsis in patients who are immunocompromised : diagnostic challenges and future therapies |
| Authors: | Deinhardt-Emmer, Stefanie Chousterman, Benjamin G. Schefold, Joerg C. Flohé, Stefanie B. Skirecki, Tomasz Kox, Matthijs Winkler, Martin S. Cossarizza, Andrea Joost Wiersinga, W. van der Poll, Tom Weigand, Markus A. Cajander, Sara Giamarellos-Bourboulis, Evangelos Lachmann, Gunnar Girardis, Massimo Scicluna, Brendon P. Ferrer, Ricard Payen, Didier Weis, Sebastian Torres, Antoni Bermejo-Martín, Jesús F. Osuchowski, Marcin F. Rubio, Ignacio Bouma, Hjalmar R. |
| Keywords: | Septicemia Immunocompromised host Immunosuppressive agents Immunological deficiency syndromes -- Complications |
| Issue Date: | 2025 |
| Publisher: | The Lancet Publishing Group |
| Citation: | Deinhardt-Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M.,...Bouma, H. R. (2025). Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. The Lancet Respiratory Medicine, 13(7), 623-637. |
| Abstract: | Sepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression and sepsis, detailing the definitions, causes, and clinical implications. We address the effect of primary immunodeficiencies, acquired conditions, and drugs on the risk of infection and the development of sepsis. Patients with sepsis who are immunocompromised often present with atypical symptoms and diagnostic test results can differ, making early recognition difficult. Future perspectives entail novel biomarkers to improve early sepsis detection and tailored treatments to modulate immune function. Including patients who are immunocompromised in clinical trials is crucial to enhance the relevance of research findings and improve treatment strategies for this vulnerable population. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/149941 |
| Appears in Collections: | Scholarly Works - FacHScABS |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Sepsis_in_patients_who_are_immunocompromised.pdf | 2.02 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.
